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Abstract: PURPOSE To evaluate the accuracy of an observational database that tracks real-world treat-
ment outcomes for neovascular age-related macular degeneration. METHODS We audited 245 ran-
domly sampled eyes from 189 patients with 3,356 visits from 11 doctors in the Fight Retinal Blindness!
DATABASE Sex, birth year, previous treatments received, treatment, and visual acuity were validated
against the clinical notes. Error rates, the proportion of missed visits (the number of visits present in the
patient record but not entered into Fight Retinal Blindness!), the level of agreement using Cohen’s kappa
(฀) and intraclass correlation coefficients, and positive and negative predictive values were calculated. A
visual acuity error was defined as an absolute difference of ฀5 letters. RESULTS The overall error rate
was 3.5% (95% confidence interval: 3.1-3.9). The error rate for visual acuity was 5.1% (95% confidence
interval: 4.2-5.9) and <5% for the remaining fields. The level of agreement for each field ranged from
good to excellent (฀ or intraclass correlation ฀ 0.75). The positive predictive value and negative predictive
value for visits were 99% and 89%, respectively. The proportion of missed visits was 10.2%. CONCLU-
SION Accuracy of the Fight Retinal Blindness! database was good (>95%). The rate of missed visits
was high, possibly due to the high burden of retrospective data entry or patients switching practitioners
during treatment.
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Purpose: To evaluate the accuracy of an observational database that tracks real-world
treatment outcomes for neovascular age-related macular degeneration.
Methods: We audited 245 randomly sampled eyes from 189 patients with 3,356 visits
from 11 doctors in the Fight Retinal Blindness! database. Sex, birth year, previous
treatments received, treatment, and visual acuity were validated against the clinical notes.
Error rates, the proportion of missed visits (the number of visits present in the patient record
but not entered into Fight Retinal Blindness!), the level of agreement using Cohen’s kappa
(k) and intraclass correlation coefficients, and positive and negative predictive values were
calculated. A visual acuity error was defined as an absolute difference of $5 letters.
Results: The overall error rate was 3.5% (95% confidence interval: 3.1–3.9). The error
rate for visual acuity was 5.1% (95% confidence interval: 4.2–5.9) and ,5% for the remain-
ing fields. The level of agreement for each field ranged from good to excellent (k or intra-
class correlation $ 0.75). The positive predictive value and negative predictive value for
visits were 99% and 89%, respectively. The proportion of missed visits was 10.2%.
Conclusion: Accuracy of the Fight Retinal Blindness! database was good (.95%). The
rate of missed visits was high, possibly due to the high burden of retrospective data entry or
patients switching practitioners during treatment.
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P
opulation-based health care databases for monitor-
ing patient outcomes in ophthalmology are becom-
ing more prevalent.1–5 Such registries can provide
valuable data for epidemiological research and health
care providers to improve quality of care.6 However,
the utility of these registries may be limited by the
quality of the data they contain, and they are rarely
validated.7 Data quality reviews of registries in other
medical fields have found that these databases are sus-
ceptible to inaccurate or missing data input.8,9
The Fight Retinal Blindness! (FRB!) project, a large
postmarketing observational registry for neovascular
age-related macular degeneration (nAMD), monitors
treatment outcomes in nAMD to provide ongoing
information regarding the efficacy, safety, and patient
preference and quality of life of treatments after their
regulatory approval. To validate the use of health care
databases as a tool for tracking real-world outcomes in
ophthalmic practice, we evaluated the accuracy of the
FRB! database by performing a retrospective audit that
compared data recorded in the database with the
doctors’ own clinical records.
Methods
Fight Retinal Blindness! Registry
Details of the FRB! observational registry have been
described previously.10 The database tracks real-world
treatment outcomes in patients with nAMD during
routine clinical practice and is compliant with the
International Consortium for Health Outcomes Meas-
urement’s age-related macular degeneration minimum
outcomes set.11 Data are entered through a web-based
interface in which the treating practitioner records
standardized information at each visit. A summary of
1
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the fields recorded in the database at baseline and sub-
sequent follow-up visits, and which fields were
included or excluded from the audit, is shown in Table
1. Practitioners participating in the registry are
required to enter data for at least 85% of patients
beginning treatment for nAMD in their practice to
satisfy the self-audit component that is required for
ongoing medical registration in Australia.
Institutional ethics approval was obtained from the
Human Research Ethics Committees of the Royal
Victorian Eye and Ear Hospital, the Royal Australian
and New Zealand College of Ophthalmologists, and
the University of Sydney. Ethics committees in
Australia and New Zealand approved the use of opt-
out patient consent. The FRB! project adhered to the
tenets of the Declaration of Helsinki.
Data Validation Procedure
Participation in the FRB! audit was voluntary.
Approximately 60 doctors in Australia and New
Zealand were contacted before conducting the audit
requesting permission for an independent reviewer to
access their patient records. We received responses
from 18 doctors agreeing to participate in the audit.
Not all of these doctors were audited either because of
logistical constraints of sending an independent
reviewer to their practice or insufficient data to justify
inclusion into the audit. The final audit included 11
doctors each with a minimum of 20 patients in the
audit who collectively contributed data for 2,344 eyes
of 1,891 patients, representing a third of the eyes
entered into the FRB! database at the time the audit
was initiated. It was estimated that a random sample of
approximately 10% of patients from each doctor
would be sufficient to give a confidence interval width
of 5% assuming an error rate of 5% in the baseline
fields. Data on both eyes were audited in patients
receiving treatment to both eyes because clinical notes
would generally keep information on both eyes
together in such cases, although baseline demograph-
ics such as birth year and sex were only checked once
per patient. All follow-up visits from sampled patients
were audited regardless of follow-up duration.
Statistical Analysis
An error was defined as a discrepancy between the
clinical records and the data as entered in the FRB!
database. An error in visual acuity was defined as an
absolute difference between the clinical record and the
FRB! database of $5 letters (1 line of vision). The
overall, field-specific and doctor-specific error rates
were estimated as the frequency of cases in which an
error was recorded divided by the total number of
entries that were checked. Cases that could not be
validated because of the unavailable source record
from the practice were excluded from the error calcu-
lation. Confidence intervals for error rates were esti-
mated assuming a binomial distribution. We also
calculated the size and distribution of all discrepancies
in visual acuity, including those that were $5 letters.
We measured the level of agreement between the
clinical and FRB! records using Cohen’s kappa statis-
tic (k) for categorical variables (sex, year of birth,
pretreatments, and treatments) and the intraclass cor-
relation for continuous variables (visual acuity). We
interpreted k and intraclass correlation based on pre-
viously suggested guidelines, with values ,0.9 indi-
cating excellent agreement, values between 0.75 and
0.9 indicating good agreement, values between 0.5 and
0.75 indicating moderate agreement, and values below
0.5 indicating poor agreement.12,13 The positive pre-
dictive value (PPV) and negative predictive value
(NPV) were calculated for treatments administered
and patient visits.
The frequency and proportion of missed visits was
also recorded. A missed visit was defined as a visit
present in the patient record that has not been entered
in the FRB! database. The proportion of missed visits
was calculated as the number of missed visits divided
by the total number of follow-up visits, both missed
and recorded. Baseline visits were excluded from this
calculation because, by definition, they could not be
missing and visits were only counted once per patient.
Analyses were conducted in R V.3.4.4 using the
psych package (V.1.8.4) to calculate k and intraclass
correlation statistics.14,15
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Results
Observations on a total of 245 eyes of 189 patients
made during 3,356 visits were audited from the FRB!
database. There were 178 visits and 10 patients from
the random sample that could not be audited because
the source record was unavailable (e.g., practice
records were missing, or patient records were offsite
at the time the reviewer attended the practice).
A summary of the overall and field-specific error
rates is shown in Table 2. The overall error rate was
estimated to be 3.5% (95% confidence interval: 3.1–
3.9) for the fields that were audited. The field with
the highest error was visual acuity, with an error rate
Table 1. List of Fields Recorded in the FRB! Database and Rationale for Excluding Fields That Were Not Validated
Field Description Visit Type Rationale for Exclusion
Sex Sex of the patient Baseline only Audited
Year of birth Birth year of the patient Baseline only Audited
Previous treatment Pretreatment status of the
patient
Baseline only Audited





Visual acuity Number of letters read on






Ethnicity Ethnicity of the patient Baseline only Subjective, may not be recorded in
clinical notes
Angiographic lesion type Lesion classification using
fluorescein angiography and/or
optical coherence
tomography, judged by the
treating clinician
Baseline only Requires assessment of images and
beyond expertise of independent
assessor
Lesion size Greatest linear dimension of
lesion
Baseline only Requires assessment of images and
beyond expertise of independent
assessor
CNV activity Lesion activity status as graded
by the treating clinician as
active if there was subretinal or





Requires assessment of images,
highly subjective and beyond the
expertise of independent
assessor




Field introduced in 2016 to comply
with ICHOM so unavailable for
most of the data. Requires
assessment of images and
beyond the expertise of
independent assessor.













Adverse events Treatment complications Follow-up only Extremely rare and unlikely to be
captured in substantial numbers
in a random sample of data.
Estimates of error likely to be
inadequate.
Discontinue reason Reason for discontinuation of the
patient from FRB! database.
This field is optional and
recorded only on the visit of
discontinuation.
Follow-up only Rare and unlikely to be captured in
substantial numbers in a random
sample of data. Entry is only
required on visit of
discontinuation, so it will not be
applicable in a majority of cases.
CNV, choroidal neovascularization; ICHOM, International Consortium for Health Outcomes Measures.
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of 5.1% (95% confidence interval: 4.3–5.9) (Figure 1).
Error rates for the remaining fields were under 5%.
The overall rate of missed visits was 10.2%. The
positive predictive value for visits was 0.991, indicating
that if a visit was present in the FRB!, then there was
a 99% chance it actually occurred. The NPV for visits
was 0.894, indicating an 89% chance that there is no
missed visit between any 2 visits recorded in the FRB!
Discrepancies in visual acuity between the FRB!
and clinical records were predominantly due to errors
in conversion from Snellen to logMAR (n = 86) or not
using the best of corrected, uncorrected, or pinhole
visual acuity (n = 58), which collectively contributed
to approximately 85% of all errors in visual acuity $5
letters. The remaining errors were possibly typograph-
ical, but otherwise the cause could not be inferred
based on the records. When considering all discrepan-
cies in visual acuity, including those within the accept-
able margin of error (,5 letter difference), the median
(Q1, Q3) difference between the FRB! and clinical
records was21 letter (25, 2). Visual acuity was lower
in the FRB! records than in the clinical records in 60%
of the cases, indicating that the FRB! values were
likely to be slight underestimates. The largest differ-
ence between the FRB! and clinical record was 76
letters. The overall distribution of all errors in visual
acuity is shown in Figure 1.
Of the 67 errors (2.0% error rate) in the treatment
field, there were 23 (34%) cases in which the FRB!
database recorded no treatment administered for that
visit despite a treatment recorded in the doctor’s re-
cords. Conversely, there were 28 (42%) cases in which
a treatment was recorded in the FRB! database despite
no treatment administered in the doctor’s records. The
remaining 16 (24%) cases were the result of the incor-
rect treatment being recorded, for example,
Table 2. Overall and Field-specific Error Rates, and the Level of Agreement Given by Cohen’s Kappa or the Intraclass
Correlation Coefficient
Field Frequency of Errors Rate of Errors, % (95% CI) Level of Agreement (95% CI)*
Sex 3 1.6 (0.4–5.0) 0.97 (0.93–1.00)
Year of birth 5 2.7 (1.0–6.4) 0.95 (0.97–1.00)
Pretreatment 7 3.7 (1.6–7.8) 0.86 (0.76–0.96)
Treatment 67 2.0 (1.6–2.6) 0.96 (0.97–0.98)
Visual acuity 168 5.1 (4.3–5.9) 0.98 (0.98–0.98)
Overall 251 3.5 (3.1–3.9) —
*Cohen’s Kappa (k) for sex, year of birth, pretreatment and treatment, and intraclass correlation for visual acuity.
CI, confidence interval.
Fig. 1. Histogram showing the
distribution of errors in visual
acuity (VA), calculated as the
FRB! record minus the clinical
record, as a percentage of all VA
discrepancies. Green bars indi-
cate the discrepancy that was
within the acceptable range of
,5 letters, whereas red bars
indicate errors that were $5
letters. The FRB! records had
lower visual acuity compared
with clinical records in 60% of
the errors, indicating the FRB!
records are slightly under-
estimating vision.
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ranibizumab instead of aflibercept. The positive pre-
dictive value for any treatment being administered was
0.989, indicating that if any treatment was recorded in
the FRB! database, then there is a 98.9% chance that
a treatment was truly administered on that visit. Con-
versely, the NPV for any treatment being administered
was 0.968, indicating that if no treatment was recorded
in the FRB! database, then there is a 96.8% chance that
no treatment was administered. For individual drugs,
the positive predictive value and NPV was 0.954 and
0.996 for bevacizumab, 0.987 and 0.993 for ranibizu-
mab, and 0.992 and 0.995 for aflibercept, respectively.
Overall doctor-specific error rates ranged from 1.5%
to 9.9% (mean: 3.8% and median: 2.5%) when
considering only clinically significant errors for visual
acuity. Doctor-specific rates of missed visits ranged
from 0% to 25.3% (mean: 5.6% and median: 5.2%).
Discussion
Observational studies have the advantage of high
external validity because they obtain data from routine
clinical practice. The FRB! project has investigated
numerous aspects of the management of nAMD since
its introduction, including outcomes of patients with
bilateral disease, persistently active lesions, different
treatment regimens, long-term treatment, adverse
events (such as endophthalmitis and retinal pigment
epithelial tears), cataract surgery, and comparison of
outcomes with Phase 3 clinical trial data.16–24
The present audit supports the validity of findings
from these previous analyses of FRB! data. We found
that there was a low overall error rate (3.5%) and good
or excellent agreement for the fields that were
analyzed (Table 2). Of these fields, visual acuity had
the highest frequency of errors, with 5.1% of entries
having a $5 letter difference between the source and
FRB! records (Figure 1). Our rates are similar to pre-
viously published audits on health registries such as
the National Cardiovascular Data Registry (83.7%–
95.7% accuracy), the National Program of Cancer
Registries (95% accuracy), and the American Heart
Association National Stroke Registry (.90% accuracy
for all but 3 variables measured).25–27 When consider-
ing all discrepancies between visual acuity recorded in
the FRB! and clinical records, the median difference
was 21 letter, indicating a slight tendency to underes-
timate visual acuity in the FRB! records but otherwise
close to the source data measurements.
Incorrect conversion of visual acuity from Snellen to
logMAR scales and not using the best recorded visual
acuity (corrected, uncorrected, or pinhole) were the
main causes of errors in visual acuity data exceeding 5
letters. We have since incorporated an automated
conversion from Snellen to logMAR visual acuity
scores into the FRB! website to reduce the frequency
of these errors, particularly for users who are not
familiar with logMAR visual acuity. There were also
some difficulties in auditing the data because of poor
legibility of information in handwritten clinical records
or different visual acuity measurements recorded by
the practitioner and their assistant at some visits.
Transitioning to an electronic health record would
eliminate mistakes in data translation due to illegible
handwriting.
There was a high rate of missed visits (10.2%) with
an NPV of 89%. Missed visits mostly occurred when
the baseline visit was recorded, but the first few years
of treatment were omitted. These were likely patients
whose baseline visit had been entered retrospectively
when the treatment had started several years earlier
and follow-up visits were then entered prospectively.
The high burden of retrospective data entry for these
patients is the most likely reason for this result. In
addition, patients who moved between providers may
also have had large gaps in their visit history, which
would contribute to the high rate of missed visits.
Timely or simultaneous data entry into the FRB!
database at the time of patient assessment, ideally by
the clinician that assesses the patient, can reduce the
rate of errors and missed visits,28 although the appeal
of tracking long-term outcomes for patients whose
data are entered retrospectively should not be ignored.
The FRB! database introduced a “treatment-only” visit
option for users in 2017, which substantially reduces
the number of mandatory fields that need to be
entered. This would ease the burden of bulk data entry
for patients with historical data to be entered, albeit at
the cost of secondary information such as lesion activ-
ity. However, a visit with reduced information is pre-
ferred to no data at all. A long-term solution toward
reducing data entry would be to introduce a single-
point data entry system whereby the relevant data from
the doctor’s electronic medical records are automati-
cally uploaded to the outcomes registry. However,
such integration is difficult because of the unstructured
nature of electronic medical records and incompatibil-
ities between different providers.
The presence of missed visits could affect published
results in a number of ways. Patients may be excluded
from analyses, for example, if they are missing key
milestone visits (e.g., 12 months) or if they do not
meet the minimum treatment requirements for inclu-
sion. Patients with large gaps in their visit history
would have likely been removed from previously
published FRB! analyses (e.g., Gillies et al29); thus,
outcomes are unlikely to have been affected although
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sample sizes would have been reduced. If patients with
missing visits are still included after applying the
selection criteria, the number of treatments would be
underestimated and intervals between treatments over-
estimated. Previously published analyses of FRB! data
have reported fewer treatments compared with clinical
trials, but more than that reported in other real-world
studies.20,30 The loss of intermediate visual acuity
measurements could also reduce resolution when esti-
mating longitudinal trends over time. Defining strict
selection criteria should reduce the impact of missed
visits on published FRB! results, although ideally such
data would be present and included in future analyses.
The errors between practitioners varied between
1.5% and 9.9%; the rate of missed visits was even
more variable, ranging from 0% to 25.3%. Although
the aims and interests of clinicians, patients, and
research institutes are likely to differ, the FRB! system
is designed to be robust and flexible to provide value
to a diverse set of users while minimizing disruption to
the users. The highly variable rate of errors is therefore
a reflection of the differing interests, value proposi-
tions, and workflows between practitioners. For exam-
ple, practitioners wishing to communicate the benefits
of treatment to patients can display the visual acuity
history for their patients, in which case the visual
acuity at baseline is necessary for context but not
necessarily all of the intermediate visits. Other users
may enter the data periodically in bulk rather than at
the time of patient assessment due to time constraints,
which could increase the chance of errors and missed
visits.
Limitations of this study include the restriction of
fields that were audited, potential bias in the selection
of practitioners who volunteered to be audited, and the
possibility that the practice records also contained
errors, the last issue further complicated by missing or
illegible clinical notes. Our study is therefore only an
approximation of the quality of data found in the FRB!
database. Error rates may be higher in fields that were
not included in this audit, such as whether a choroidal
neovascularization lesion was active or not. Adverse
events and reasons for discontinuation were not
included in our study because of the infrequency of
these events, and it is possible that they are under-
reported in the FRB! database. Fields designed to
capture data that require the interpretation of images
such as lesion activity, subretinal fibrosis, or geo-
graphic atrophy are vulnerable to observational bias
and may require an independent reading center audit to
adjudicate their grading. Recent advances in machine
learning for image analysis could be a solution to
reduce subjectivity and possibly reduce errors in fields
requiring image assessment, if they are found to be
unacceptably high.31,32 However, there is a distinction
to be made between errors in data entry, which was the
focus of this audit, and misdiagnoses by clinicians,
which is a much larger issue and beyond the scope
of this study. Selection bias may also be present
because participation in this data quality review was
entirely voluntary. This self-selected group of practi-
tioners from the FRB! database may have lower error
rates or better compliance than the remaining practi-
tioners who did not respond or refused to participate in
the review. Indeed, these doctors collectively contrib-
uted to approximately a third of the overall data, sug-
gesting that they are highly active within the registry.
This audit has demonstrated that there is a high
accuracy rate of data recorded in the FRB! registry.
Automated conversion of visual acuity from Snellen
and logMAR should further reduce errors, particularly
for users unfamiliar with logMAR. The rate of missed
visits was high and likely due to the high burden of
retrospective data entry. Treatment-only visits with
fewer mandatory fields were introduced to reduce this
burden. Single-point data entry is an ideal long-term
solution toward reducing the burden of data entry;
however, implementing such a system poses several
challenges. Ongoing audits of observational registries
are necessary to ensure maintenance of an adequate
quality of data that is appropriate for analysis.
Key words: observational data, registry, data
quality, audit.
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